Development of Novel Combination Therapies
The DOI matches its Crossref record.
Abstract
Successful development of future targeted therapies will require the flexibility to rapidly evaluate combination regimens involving new targeted agents in a single development program. The FDA has therefore developed draft guidance on drug co-development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Mechanisms of NAFLD development and therapeutic strategies
Friedman, S. L., Neuschwander-Tetri, B. A., Rinella, M., & Sanyal, A. J. (2018) · Nature Medicine · doi:10.1038/s41591-018-0104-9 · Cited by 4,354
Combinatorial drug therapy for cancer in the post-genomic era
Al-Lazikani, B., Banerji, U., & Workman, P. (2012) · Nature Biotechnology · doi:10.1038/nbt.2284 · Cited by 1,070
Analysis of drug combinations: current methodological landscape
Foucquier, J., & Guedj, M. (2015) · Pharmacology Research & Perspectives · doi:10.1002/prp2.149 · Cited by 1,115
“In this context, recommendations from the US Food and Drug Administration (FDA) [Codevelopment of Two or More New Investigational Drugs for Use in Combination, 2013], the European Medicines Agency (EMA) [Guideline on fixed combination medicinal products, 2008] and the World Health Organization (WHO) [Guidelines for re…”
BackgroundInfluentialNanoparticle-based combination therapy toward overcoming drug resistance in cancer
Hu, C.-M. J., & Zhang, L. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.01.008 · Cited by 686
Nanogels: An overview of properties, biomedical applications and obstacles to clinical translation
Soni, K. S., Desale, S. S., & Bronich, T. K. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.009 · Cited by 683
Reengineering Translational Science: The Time Is Right
Collins, F. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002747 · Cited by 479
Duan, X., Xiao, J., Yin, Q., Zhang, Z., Yu, H., Mao, S., & Li, Y. (2013) · ACS Nano · doi:10.1021/nn4010796 · Cited by 379
Nanoparticles for combination drug therapy
Ma, L., Kohli, M., & Smith, A. (2013) · ACS Nano · doi:10.1021/nn405674m · Cited by 367
Role of integrated cancer nanomedicine in overcoming drug resistance
Iyer, A. K., Singh, A., Ganta, S., & Amiji, M. M. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.07.012 · Cited by 343
Xu, X., Xie, K., Zhang, X.-Q., Pridgen, E. M., Park, G. Y., Cui, D. S., Shi, J., Wu, J., Kantoff, P. W., Lippard, S. J., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303958110 · Cited by 340
“It is generally accepted that cancer is usually the result of a combination of interconnected disease pathways that may not be treated effectively with 1D therapeutic mechanisms (1).”
Duarte, D., & Vale, N. (2022) · Current Research in Pharmacology and Drug Discovery · doi:10.1016/j.crphar.2022.100110 · Cited by 340
Zhu, H., Cheng, P., Chen, P., & Pu, K. (2018) · Biomaterials Science · doi:10.1039/c7bm01210a · Cited by 297
Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval
Eichler, H.-G., Oye, K., Baird, L. G., Abadie, E., Brown, J., L Drum, C., Ferguson, J., Garner, S., Honig, P., Hukkelhoven, M., et al. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.345 · Cited by 271
Adaptive clinical trials in oncology
Berry, D. A. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.165 · Cited by 267
A Perspective on Multi-target Drugs for Alzheimer’s Disease
Benek, O., Korabecny, J., & Soukup, O. (2020) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2020.04.008 · Cited by 260
Wang, C., Sun, X., Cheng, L., Yin, S., Yang, G., Li, Y., & Liu, Z. (2014) · Advanced Materials · doi:10.1002/adma.201400158 · Cited by 252
Inhaled formulations and pulmonary drug delivery systems for respiratory infections
Zhou, Q. (., Leung, S. S. Y., Tang, P., Parumasivam, T., Loh, Z. H., & Chan, H.-K. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.022 · Cited by 246
“Hence, combination therapies containing different types of antibiotics have been extensively used clinically to prevent the emergence of drug resistance [128].”
Molecular Communication and Nanonetwork for Targeted Drug Delivery: A Survey
Chude-Okonkwo, U. A. K., Malekian, R., Maharaj, B. T., & Vasilakos, A. V. (2017) · IEEE Communications Surveys & Tutorials · doi:10.1109/comst.2017.2705740 · Cited by 208
“This form of therapeutic modality is often termed combination therapy, which defines the use of more than one modality of medication in a therapeutic process [144].”
BackgroundXiao, H., Song, H., Yang, Q., Cai, H., Qi, R., Yan, L., Liu, S., Zheng, Y., Huang, Y., Liu, T., et al. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.05.049 · Cited by 200
PEG- b -PLA micelles and PLGA- b -PEG- b -PLGA sol–gels for drug delivery
Cho, H., Gao, J., & Kwon, G. S. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.12.015 · Cited by 186
“drug combinations that attack aberrant cancer cell signaling [1-4].”
BackgroundSynergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen
Ramón-García, S., Ng, C., Anderson, H., Chao, J. D., Zheng, X., Pfeifer, T., Av-Gay, Y., Roberge, M., & Thompson, C. J. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00474-11 · Cited by 185
Geary, N. (2013) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00308.2012 · Cited by 165
Design strategies and applications of cyanine dyes in phototherapy
Yuan, J., Yang, H., Huang, W., Liu, S., Zhang, H., Zhang, X., & Peng, X. (2025) · Chemical Society Reviews · doi:10.1039/d3cs00585b · Cited by 143
Tummala, S., Gowthamarajan, K., Satish Kumar, M. N., & Wadhwani, A. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1084400 · Cited by 61
Yenilmez, B., Wetoska, N., Kelly, M., Echeverria, D., Min, K., Lifshitz, L., Alterman, J. F., Hassler, M. R., Hildebrand, S., DiMarzio, C., et al. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.007 · Cited by 46
Charting a path toward combination therapy for Alzheimer’s disease
Stephenson, D., Perry, D., Bens, C., Bain, L. J., Berry, D., Krams, M., Sperling, R., Dilts, D., Luthman, J., Hanna, D., et al. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.995168 · Cited by 37
“Recognizing the need for regulatory guidance on the development of novel combinations of investigational drugs, the US FDA in 2010 issued a draft guidance on what the FDA defines as co-development, that is, the development of two novel compounds intended to be used together, not as add-ons to existing drugs [14,15].”
Background
Metadata
- Authors
- Woodcock, J., Griffin, J. P., & Behrman, R. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-03-17
- Volume
- 364
- Issue
- 11
- Pages
- 985-987
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2053470367
- Cited by
- 248
- References
- 0
- FWCI
- 18.92
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.